VLP Biotech

Executive Summary

VLP Biotech, founded in 2013 and based in San Diego, is a private biotechnology company developing a proprietary vaccine platform that engineers custom recombinant proteins for antibody production and vaccine development. The company specializes in infectious disease vaccines, with active research programs targeting malaria, MRSA, and RSV. Its platform focuses on virus-like particles (VLPs) to elicit robust immune responses. Despite being in early stages, VLP Biotech's differentiated approach addresses critical unmet needs in global health. The company has not disclosed significant funding rounds or partnership deals, suggesting it remains in preclinical or early clinical development. Given the competitive landscape and technical risks, VLP Biotech's progress will depend on advancing its lead candidates into clinical trials and securing strategic collaborations.

Upcoming Catalysts (preview)

• Q2 2026Initiation of Phase 1 trial for malaria VLP vaccine candidate20% success
• TBDAnnouncement of partnership or licensing deal for RSV or MRSA program15% success
• Q3 2026Publication of preclinical efficacy data in peer-reviewed journal30% success